Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia
Phase 2
Recruiting
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)
- Interventions
- Drug: QHRD107 capsule，Venclexta and Azacitidine
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT06532058
- Locations
- 🇨🇳
The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
🇨🇳Zhongda Hospital, Nanjing, Jiangsu, China
🇨🇳ShengJing Hospital, Shenyang, Liaoning, China
Study to Assess PK, Safety and Tolerability Early in Healthy Subjects
Phase 1
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: QHRD106 InjectionDrug: placebo
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
- Target Recruit Count
- 74
- Registration Number
- NCT06388772
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
Study to Assess PK, Safety and Tolerability in Healthy Subjects
Phase 1
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT06380699
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
© Copyright 2025. All Rights Reserved by MedPath